期刊
ENDOCRINE PRACTICE
卷 22, 期 3, 页码 350-356出版社
AMER ASSOC CLINICAL ENDOCRINOLOGISTS
DOI: 10.4158/EP15913.RA
关键词
-
资金
- Novartis Pharmaceuticals Corporation
Objective: In a completed phase III study (C2305, Clinicaltrials.gov identifier: NCT00600886), the reported rate of biochemical control with octreotide long-acting release (LAR) was lower than rates historically reported in patients pretreated and/or selected for response with somatostatin analogue (SSA) therapy. To assess whether lower efficacy rates of octreotide LAR in C2305 were influenced by study design, a systematic review of the literature was performed to evaluate response rates in previously published studies in acromegaly with similar design characteristics. Methods: PubMed was used to search for English-language clinical studies of acromegaly published through May 2014. Prospective studies of medically naive patients (>= 20) treated with SSAs for <= 12 months that reported efficacy rates using composite endpoint measures (growth hormone [GH] and insulin-like growth factor 1 [IGF-1]) were included. Two separate authors independently screened abstracts and full-length articles of each study to determine eligibility. All authors met to review and reach consensus when primary reviewers disagreed on the inclusion or exclusion of specific studies. Results: A total of 9 studies (N = 354 patients) were identified, with reported mean efficacy rates of 31% (range, 20-54%). Of note, reported mean efficacy rates were lower in studies enrolling patients naive to any form of treatment (surgery, medical, and/or radiation) than in studies that enrolled only medically naive patients. A limitation of this analysis was that inclusion criteria restricted the number of studies analyzed. Conclusion: Interpretation of biochemical response rates with SSAs is critically dependent on the context of the study and should be evaluated across clinical trials with similar study design characteristics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据